1. Home
  2. VITL vs IVVD Comparison

VITL vs IVVD Comparison

Compare VITL & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vital Farms Inc.

VITL

Vital Farms Inc.

HOLD

Current Price

$10.01

Market Cap

434.1M

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.01

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VITL
IVVD
Founded
2007
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
434.1M
437.1M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
VITL
IVVD
Price
$10.01
$1.01
Analyst Decision
Buy
Strong Buy
Analyst Count
11
5
Target Price
$32.00
$8.75
AVG Volume (30 Days)
3.9M
2.9M
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
22.03
79.02
EPS
N/A
N/A
Revenue
$759,444,000.00
$53,426,000.00
Revenue This Year
$19.72
$61.57
Revenue Next Year
$17.02
$41.42
P/E Ratio
N/A
N/A
Revenue Growth
25.26
110.47
52 Week Low
$7.95
$0.49
52 Week High
$53.13
$3.07

Technical Indicators

Market Signals
Indicator
VITL
IVVD
Relative Strength Index (RSI) 45.13 34.26
Support Level $7.95 $0.49
Resistance Level $10.60 $1.14
Average True Range (ATR) 0.62 0.09
MACD 0.23 0.00
Stochastic Oscillator 77.19 9.58

Price Performance

Historical Comparison
VITL
IVVD

About VITL Vital Farms Inc.

Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: